Skinvisible, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SKVI research report →
Price Chart
About the company
Skinvisible, Inc. , together with its associated entities, specializes in the creation, production, and distribution of advanced polymer-based delivery system technologies. These proprietary systems facilitate the topical, transdermal, and mucosal application of active ingredients, serving various sectors including pharmaceuticals (both prescription and over-the-counter), personal skincare, and cosmetics.
- CEO
- Terry H. Howlett
- IPO
- 1999
- Employees
- 2
- HQ
- Las Vegas, NV, US
Get TickerSpark's AI analysis on SKVI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.09M
- P/E
- -1.04
- PEG
- 0.01
- P/S
- 54.74
- P/B
- -0.10
- EV/EBITDA
- -15.53
- Div Yield
- 0.00%
- Gross Margin
- -1.20%
- Op Margin
- -2294.90%
- Net Margin
- -5156.60%
- ROE
- 9.92%
- ROIC
- 9.07%
Latest fiscal year · YoY change
- Revenue
- $20.00K+0.0%
- Gross Profit
- $-239+45.4%
- Op Income
- $-496,315
- Net Income
- $-1,064,034-88.1%
- EPS
- $-0.20-81.8%
- OCF Growth
- +45.0%
- FCF Growth
- +46.2%
- 52W High
- $0.90
- 52W Low
- $0.14
- 50D MA
- $0.21
- 200D MA
- $0.27
- Beta
- 1.71
- RSI (14)
- 47
- Avg Volume
- 281
No earnings-call transcripts are available for SKVI yet.
- Free Float
- 96.5%
- Shares Outstanding
- 5.40M
- Float Shares
- 5.21M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 31, 23 | MCMORRAN DOREEN | other | 12,562,975 |
| Jan 31, 23 | MCMORRAN DOREEN | other | 25,125,950 |
| Jan 31, 23 | HOWLETT TERRY | other | 14,299,035 |
| Jan 31, 23 | HOWLETT TERRY | other | 28,598,070 |
| Jun 30, 19 | MCMORRAN DOREEN | other | 5,144,755 |
| Jun 30, 19 | MCMORRAN DOREEN | other | 10,289,510 |
| Jun 30, 19 | HOWLETT TERRY | other | 5,443,268 |
| Jun 30, 19 | HOWLETT TERRY | other | 10,886,535 |
| Mar 28, 18 | MCMORRAN DOREEN | sell | 1 |
| Dec 31, 18 | MCMORRAN DOREEN | other | 1 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SKVI coverage
Recent articles, reports, and earnings notes.
No research on SKVI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SKVI report →Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
accessnewswire.com · Sep 18
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
accessnewswire.com · Jan 23
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
accesswire.com · Oct 3
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
accesswire.com · Jul 11
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
accesswire.com · Jun 24
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
accesswire.com · Feb 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.